Dyadic International, Inc.
$0.88
▲
4.45%
2026-04-21 06:32:00
www.dyadic.com
NCM: DYAI
Explore Dyadic International, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$31.88 M
Current Price
$0.88
52W High / Low
$1.35 / $0.65
Stock P/E
—
Book Value
$0.03
Dividend Yield
—
ROCE
-114.18%
ROE
-3.98%
Face Value
—
EPS
$-0.23
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.21
Debt / Equity
410.63
Current Ratio
2.68
Quick Ratio
2.68
Forward P/E
-2.78
Price / Sales
10.5
Enterprise Value
$30.2 M
EV / EBITDA
—
EV / Revenue
9.77
Rating
Strong Buy
Target Price
$7
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Atea Pharmaceuticals, Inc. | $5.71 | — | $457.32 M | — | -65.67% | -44.34% | $6.45 / $2.46 | $3.52 |
| 2. | Actuate Therapeutics, Inc. Common stock | $2.62 | — | $54.77 M | — | -270.08% | -5.54% | $11.99 / $1.58 | $0.34 |
| 3. | Tyra Biosciences, Inc. | $34.37 | — | $1.92 B | — | -50.19% | -39.83% | $40.65 / $7.8 | $4.83 |
| 4. | CorMedix Inc. | $7.58 | 3.58 | $584.18 M | — | 23.03% | 66.56% | $17.43 / $6.13 | $5.11 |
| 5. | Aspire Biopharma Holdings, Inc. | $0.26 | — | $1.36 M | — | 308.11% | 618.48% | $35 / $0.22 | $-1.8 |
| 6. | MetaVia Inc. | $1.51 | — | $7.13 M | — | -250.37% | -1.96% | $19.03 / $1.17 | $2.31 |
| 7. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.24 M | 0.35 M | 0.46 M | 0.18 M | 0.82 M | — |
| Operating Profit | -1.52 M | -1.91 M | -1.71 M | -2 M | -1.52 M | — |
| Net Profit | -1.57 M | -1.98 M | -1.79 M | -2.03 M | -1.55 M | — |
| EPS in Rs | -0.04 | -0.05 | -0.05 | -0.06 | -0.04 | -0.01 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.23 M | 3.5 M | 2.9 M | 2.93 M |
| Operating Profit | -7.15 M | -5.88 M | -8.19 M | -10.12 M |
| Net Profit | -7.36 M | -5.81 M | -6.8 M | -9.74 M |
| EPS in Rs | -0.2 | -0.16 | -0.19 | -0.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.95 M | 9.93 M | 8.22 M | 13.71 M |
| Total Liabilities | 8.71 M | 7.46 M | 2.34 M | 2.63 M |
| Equity | 1.23 M | 2.47 M | 5.88 M | 11.09 M |
| Current Assets | 9.9 M | 9.83 M | 8.07 M | 13.42 M |
| Current Liabilities | 3.69 M | 2.45 M | 2.25 M | 2.45 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.7 M | -3.97 M | -6.73 M | -8.08 M |
| Investing CF | 0.08 M | -1.88 M | 7.45 M | -2.37 M |
| Financing CF | 4.96 M | 5.85 M | 0 M | 0.54 M |
| Free CF | -5.7 M | -3.97 M | -6.73 M | -8.08 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 20.58% | -1.07% | — | — |
| Earnings Growth % | 14.51% | 30.2% | — | — |
| Profit Margin % | -166.19% | -234.42% | -332.23% | — |
| Operating Margin % | -168.17% | -282.58% | -345.21% | — |
| Gross Margin % | 65.82% | 31.84% | 27.54% | — |
| EBITDA Margin % | -153.95% | -234.42% | -345.21% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.